Iridex Corporation reported a net loss of $1.3 million [1] for the second quarter of 2026.
The results highlight the financial volatility facing the medical technology firm as it balances growth in specific treatment segments against operational overhead and relocation costs.
Based in Mountain View, California, the company reaffirmed its full-year 2026 revenue guidance of $51 million to $53 million [2]. The announcement came during an earnings release on Tuesday, Aug. 20 [3].
Management identified a cash-flow inflection point during the period. The company said growth occurred within its glaucoma segment, though this was offset by headwinds in the retina segment [4].
Financial pressures were further compounded by a build in working capital. Iridex said these needs are tied to the relocation of its headquarters [4].
The company continues to navigate these internal transitions while maintaining its outlook for the remainder of the year. The balance of growth in glaucoma against the retina segment's struggles remains a central focus for the firm's fiscal trajectory [4].
“Iridex Corporation reported a net loss of $1.3 million for the second quarter of 2026.”
The reaffirmation of revenue guidance suggests that while Iridex is facing short-term losses and logistical expenses from its move, the underlying demand for its products remains stable. However, the divergence between the growing glaucoma segment and the struggling retina segment indicates a shift in the company's primary value drivers.
